Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | List with clinical criteria and/or conditions | Complete | ||
| Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending | |||
| Isentress | Raltegravir | HIV | List with clinical criteria and/or conditions | Complete | ||
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
| Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
| Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 30, 2024